Alnylam presents positive phase 3 results from illuminate-a study of lumasiran, an investigational rnai therapeutic for treatment of primary hyperoxaluria type 1

Alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today positive phase 3 results from the illuminate-a st
ALNY Ratings Summary
ALNY Quant Ranking